In vivo and ex vivo imaging studies indicated that A2-APM quickly detected the low-density lipoprotein receptor-related protein 1 (LRP1) on endothelial cells and GBM cells after intravenous treatment, to boost aPD-L1 and PTX entry into the tumor environment of GBM, resulting in substantially increased accumulation of antibodies in the brain in several tumor xenograft models, compared to free aPD-L1 group. This evidence concerns the gene LRP1 and glioblastoma.